Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Axel Hauschild(University Hospital Schleswig-Holstein), Claus Garbe(University of Tübingen), Michael R. Migden(The University of Texas MD Anderson Cancer Center), J. Fernando Quevedo(Mayo Clinic), Anja Gesierich(University of Michigan), Edward McKenna(Roche (United Kingdom)), Omid Hamid(Cedars-Sinai Medical Center), Natalie Dimier(Roche (United Kingdom)), Dirk Schadendorf(National Center for Tumor Diseases), Nicole Basset‐Séguin(Université Paris Cité), Laurent Mortier, Aleksandar Sekulić(The University of Texas MD Anderson Cancer Center), Sarah Williams(Ruhrlandklinik), Christopher D. Lao(University of Michigan), Chris Miller(University of California, Davis), Dédée F. Murrell(Sutherland Hospital), Jeannie Hou
Cited by 412
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k